- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00664937
Exercise Induced Bronchoconstriction (0476-359)
January 31, 2022 updated by: Organon and Co
A 3 Period, Double-Blind, Randomized Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo on Exercise-Induced Bronchoconstriction as Assessed by Hyperpolarized Gas Magnetic Resonance Imaging.
Exercise-induced bronchoconstriction (EIB) is a condition where airways tighten when you exercise and may cause coughing, wheezing, or shortness of breath.
In many patients, this condition can cause lung function to drop making it harder to breath.
An instrument called a spirometer is commonly used to measure lung function.
This traditional means of assessing lung function in asthma is limited in its ability to provide information as to where in the lung the tightness is.
Hyperpolarized helium magnetic resonance imaging (3He MRI) is a novel way to see the where air is going in the lungs using an MRI and special gas.
The ability to see where the air can and cannot reach in the lungs may help show more accurately if a medication is working to make the asthma better.
The purpose of this study is to examine patients with EIB in order to see if 3He MRI provides a better way to measure lung function.
Patients will be given either montelukast sodium, a drug to improve the ability to breath with EIB, or placebo and then put on a treadmill to induce an occurrence of airway constriction.
The patient's lung function will be measured more than once using both the spirometer and the 3He MRI.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is a man or woman who is between the ages of 18 and 55 years of age at Visit 1
- Female patients of that are of childbearing potential must show they are not pregnant either by blood test Visit 1 and agree to use appropriate single barrier or hormonal contraception during the course of the study and continuing for at least 14 days following the patient's last study visit
- The patient has stable asthma without any worsening (e.g., requiring unscheduled visit to a physician, hospital or other healthcare resource, new medications or change in dose or frequency of current medications) within 4 weeks of Visit 1 and Visit 2
- Patient is a current non-smoker and if has a history of smoking, has not smoked for at least 6 months and has a smoking history of no more than 15 pack-years (i.e., 1 pack per day for 15 years)
Exclusion Criteria:
- Patient has donated a unit of blood within 4 weeks prior to Visit 1 or anticipates donating blood at any time during this study
- Patient has participated in a clinical trial involving an investigational or marketed medication within the 4 weeks prior to Visit 1 or anticipates participating in any other clinical trial during this study. Patient is currently a regular user, or a recent past abuser (within the past 5 years), of alcohol or illicit drugs
- Patient is a female who has given birth in the last 8 weeks of Visit 1 or breast feeding an infant
- Patient is pregnant, or intends to become pregnant during the time course of the study. Patient is hospitalized or has had a major surgical procedure, major trauma requiring medical attention, or significant illness requiring medical attention within 4 weeks of Visit 1
- Patient does not agree to limit caffeinated beverages and/or chocolate within 8 hours of study visits. Patient has had a worsening of their asthma within 4 weeks of Visit 1 or Visit 2 (i.e., requiring change in type, dose or frequency of medications and/or an unscheduled visit to a health care provider, including emergency room or hospital). Patient has unresolved signs and/or symptoms of an upper respiratory tract infection within 4 weeks of Visit 1 or Visit 2
- Patient is unwilling to restrict vigorous exercise (e.g., weight lifting or long distance running) or abstain from performing strenuous activity within 18 hours of any visit
- Patient has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to: pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures) and/or ear implants
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: I
Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge.
For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
|
single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
Other Names:
single oral dose, before exercise challenge, of Pbo; 7 week duration.
|
Placebo Comparator: II
Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge.
For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
|
single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
Other Names:
single oral dose, before exercise challenge, of Pbo; 7 week duration.
|
Placebo Comparator: III
Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge.
For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
|
single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
Other Names:
single oral dose, before exercise challenge, of Pbo; 7 week duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ventilation volume by 3He MRI, ventilation volume defects by 3He MRI, pulmonary lung function by spirometer
Time Frame: 5 minutes to 1 hour after exercise challenege
|
5 minutes to 1 hour after exercise challenege
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reproducability of ventilation volume and ventilation volume defects as measured by 3He MRI
Time Frame: 3-7 days apart.
|
3-7 days apart.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
April 22, 2008
First Submitted That Met QC Criteria
April 22, 2008
First Posted (Estimate)
April 23, 2008
Study Record Updates
Last Update Posted (Actual)
February 14, 2022
Last Update Submitted That Met QC Criteria
January 31, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Asthma, Exercise-Induced
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- 0476-359
- MK0476-359
- 2008_502
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma, Exercise-induced
-
Johann Wolfgang Goethe University HospitalCompleted
-
Forest LaboratoriesCompleted
-
Universita di VeronaCompleted
-
Indiana UniversityRecruitingExercise Induced Bronchospasm | Exercise Induced AsthmaUnited States
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
-
Skane University HospitalSwedish Heart Lung FoundationCompletedRespiratory Function Tests
-
Johann Wolfgang Goethe University HospitalCompletedExercise Induced Asthma | Exercise Induced Pharyngeal CollapseGermany
-
University of ArizonaGlaxoSmithKlineCompletedExercise Induced Bronchospasm, AsthmaUnited States
Clinical Trials on montelukast sodium
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Torrent Pharmaceuticals LimitedCompleted
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Bugra KergetNot yet recruiting
-
Torrent Pharmaceuticals LimitedCompleted
-
Kecioren Education and Training HospitalCompletedAcute Asthma | Acute Wheezy BronchitisTurkey
-
Medical University of LodzUnknownSeasonal Allergic RhinitisPoland
-
Indiana UniversityCompleted